ERBB2 and breast carcinoma: These results indicate that ET combined with HER2-targeted therapy may represent a viable first-line treatment option for chemotherapy-intolerant patients or those with favorable prognostic characteristics, especially treatment-naïve patients with de novo advanced breast cancer who tend to respond better to targeted therapies.